Form 4: Clover Health Director Granted 79,365 RSUs

Clover Health Investments Corp. director William G. Robinson Jr. was granted 79,365 restricted stock units, vesting in January 2027.

Summary

• Director William G. Robinson Jr. of Clover Health Investments, Corp. was granted 79,365 shares of Class A Common Stock in the form of time-based Restricted Stock Units (RSUs).
• The transaction date for the grant was January 6, 2026.
• These RSUs will vest in full on January 6, 2027, contingent upon Mr. Robinson's continued service as a director.
• Following this transaction, Mr. Robinson beneficially owns 597,987 shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a neutral event. It aligns director interests with shareholders but also represents potential future dilution. The pre-planned nature (10b5-1) is a positive for transparency.

Positives

• The grant of Restricted Stock Units (RSUs) aligns the director's interests with long-term shareholder value, as vesting is contingent on continued service and potential stock price appreciation.
• The use of a Rule 10b5-1(c) plan indicates a pre-planned transaction, which can reduce concerns about insider trading.

Negatives

• The grant of RSUs at a $0 price represents dilution for existing shareholders, although it is a common form of executive and director compensation.

Risks

• The vesting of the RSUs is subject to the director's continued service, meaning the shares could be forfeited if service is terminated before January 6, 2027.

Future Outlook

The vesting schedule for the RSUs on January 6, 2027, indicates a commitment to the director's continued service for at least another year.

Industry Context

This is a routine insider transaction for director compensation, common across publicly traded companies, particularly in the healthcare technology sector where attracting and retaining experienced board members is crucial.

Comparison to Industry Standards

• The grant of time-based Restricted Stock Units (RSUs) to directors is a standard practice in corporate governance for public companies, including those in the healthcare and technology sectors like Clover Health.
• The size of the grant (79,365 shares) for a director should be evaluated against peer companies in the healthcare technology space, such as Oscar Health (OSCR) or Bright Health Group (BHG), to determine if it is within typical ranges for director compensation.
• The $0 acquisition price is typical for RSU grants, reflecting compensation rather than a purchase.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon vesting, but also increased alignment of director's interests with long-term stock performance.
• Director (William G. Robinson Jr.): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The 79,365 Restricted Stock Units are scheduled to vest on January 6, 2027, contingent on the director's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director as part of their compensation package. Such grants are common practice and generally do not provide new information that would warrant a change in investment recommendation. While it aligns the director's interests with shareholders, the minor dilution is expected. Therefore, a 'hold' recommendation is appropriate as this event does not fundamentally alter the company's investment thesis.

Keywords

Clover Health, CLOV, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Award, William G. Robinson Jr., 10b5-1 Plan